不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向 CD19 的弥漫大 B 细胞淋巴瘤免疫治疗
英文原题：CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma.
查看英文原题
CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多年来，手术切除、化疗和放疗是仅有的癌症治疗方法。近期，免疫检查点抑制剂和过继细胞疗法作为有前景的替代选择逐渐出现。这些癌症免疫疗法旨在支持或利用患者免疫系统识别并摧毁癌细胞。临床前和临床研究已显示显著成果：将T细胞、近期也包括NK细胞进行嵌合抗原受体基因工程改造，使过继细胞疗法重新靶向肿瘤细胞。本文概述弥漫大B细胞淋巴瘤（DLBCL）免疫疗法的最新进展，重点关注CD19靶向免疫疗法，并讨论当前临床试验及免疫疗法治疗DLBCL患者的机会。
展开英文摘要原文
Surgical resection, chemotherapy and radiotherapy were, for many years, the only available cancer treatments. Recently, the use of immune checkpoint inhibitors and adoptive cell therapies has emerged as promising alternative. These cancer immunotherapies are aimed to support or harness the patient's immune system to recognize and destroy cancer cells.
Preclinical and clinical studies, based on the use of T cells and more recently NK cells genetically modified with chimeric antigen receptors retargeting the adoptive cell therapy towards tumor cells, have already shown remarkable results. In this review, we outline the latest highlights and progress in immunotherapies for the treatment of Diffuse Large B-cell Lymphoma (DLBCL) patients, focusing on CD19-targeted immunotherapies.
We also discuss current clinical trials and opportunities of using immunotherapies to treat DLBCL patients.
论文信息
- 作者
- Gambella M、Carlomagno S、Raiola AM、Giannoni L、Ghiggi C、Setti C、Giordano C、Luchetti S
- 第一作者单位
- Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.Italy
- 通讯作者单位
- Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy.Italy
- 文献类型
- 非美国政府资助研究 · 综述
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 35280988 · DOI 10.3389/fimmu.2022.837457
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →